CHAPEL HILL -The University of North Carolina at Chapel Hill is teaming up with the National Football League to measure on-field head impacts using high-tech
To embed, copy and paste the code into your website or blog:
Earlier this year, the European Data Protection Board (“EDPB”) issued additional guidance on the application of the General Data Protection Regulation (“GDPR”) in the area of scientific health research.
In key takeaways from the guidance, the EDPB:
Confirmed that the informed consent that individuals must provide under ethical standards to participate in scientific research (including clinical trials) is to be distinguished from Art. 9(2)(a) GDPR (and, therefore, legal grounds other than consent, provided under Articles 6 and 9, may be relied upon for processing health data);
Confirmed that the processing of personal data for scientific research may rely on Member State law that specifically authorizes such processing, under Art. 9(2)(j);
PolyNovo says COVID-19 surge slowed US second quarter sales
Save
Share
Biotech PolyNovo managing director Paul Brennan says predicting the sales trajectory in its key market the United States is “challenging” after revealing revenue growth for its skin regeneration technology had slowed in the second quarter as hospital capacity was filled by surging COVID-19 cases.
The $1.95 billion company makes dermal regeneration solutions, NovoSorb BTM, using its NovoSorb biodegradable polymer technology.
PolyNovo s Paul Brennan said forecasting sales would be challenging, particularly in the US, but the medium-term outlook was strong.
Eamon Gallagher
NovoSorb BTM is a dermal scaffold for the regeneration of the skin when lost through extensive surgery or burns. It speeds up patient recovery times and reduces the chance of infections, compared with traditional animal-sourced biological scaffolds.
Why did the PolyNovo share price rocket higher in 2020?
A series of positive announcements by PolyNovo during 2020 helped drive its shares higher.
One of those was the announcement of its full year results for FY 2020. Which, despite the COVID-19 pandemic, saw the company double its NovoSorb BTM sales revenue to $19.1 million.
This was driven by strong growth in all markets, but particularly in the United States. The company’s US business delivered a record quarterly sales result in the March quarter and then followed it up with a 36% increase in sales compared to the prior corresponding period during the June quarter.